21 CFR 211 requirements for finished pharmaceutical drugs
21 CFR 211 sets FDA's CGMP rules for finished drugs. Learn how Part 210 fits, who the rules cover, and what Subparts A to K require for manufacturing.
21 CFR 211 sets FDA's minimum current good manufacturing practice (CGMP) requirements for finished human and animal drug products, with stated exclusions. Part 210 supplies the general provisions, applicability rules and definitions. Part 211 then sets the operational requirements, in Subparts A to K.
These are binding regulations in Title 21 of the Code of Federal Regulations, not optional FDA guidelines. Section 210.1(b) says failure to comply renders the drug adulterated under section 501(a)(2)(B) of the act, and subjects the drug and the responsible person to regulatory action.
How 21 CFR Parts 210 and 211 fit together
Read 21 CFR 210 with 21 CFR 211. Section 210.1 addresses methods, facilities and controls used in manufacturing, processing, packing or holding drugs. Part 211 then sets requirements for finished pharmaceutical products, including personnel, equipment, production, laboratories and records.
A "drug product" is a finished dosage form, such as a tablet, capsule or solution. The definition also includes an intended placebo. Section 211.3 applies the definitions in section 210.3 to Part 211. Do not treat that finished-product definition as covering every active-ingredient operation. Check the requirements that apply to the operation.
For a compliance assessment, start with the product and the operations performed. Then use Part 210 to establish applicability before mapping the relevant Part 211 requirements to those operations.
Who must follow Part 211?
Part 211 covers human and animal drug products within its scope. Section 211.1(a) expressly excludes positron emission tomography drugs and medical gases as defined in section 213.3(b)(12).
Part 211 does not cover every finished medicine.
The medical-gas exclusion reflects FDA's medical-gases final rule, published on 18 June 2024. Its Part 211 amendments took effect on 18 December 2025. Use the amended scope when assessing current applicability.
Other scope points affect how a manufacturer applies the rules:
- Applicable biologics and human-cell/tissue-product regulations supplement Part 211. They do not supersede it unless a regulation explicitly says so. Where they conflict, the provision specific to the drug product governs. See section 211.1(b) and section 210.2(a).
- A business performing only some regulated operations must comply with requirements applicable to those operations. Section 210.2(b) does not create a blanket exemption for contract businesses.
- Qualifying Phase 1 investigational-drug production is exempt from Part 211. It remains subject to statutory CGMP under 21 U.S.C. 351(a)(2)(B). That exemption ends once the drug has been made available for Phase 2 or 3 use by or for the sponsor, or lawfully marketed. Subsequent Phase 1 use must then comply with Part 211. See section 210.2(c).
These are US requirements, not UK domestic law. They matter to applicable US-market operations outside the United States too. FDA states that it inspects pharmaceutical manufacturing facilities worldwide, including facilities making active ingredients and finished products.
What Part 211 Subparts A to K cover
Use this table to find the relevant section before reading its full requirements. The ranges show each subpart's first and last sections; some intervening section numbers are absent.
| Subpart | Official heading | Section range | Practical focus |
|---|---|---|---|
| A | General Provisions | 211.1–211.3 | Scope and definitions |
| B | Organization and Personnel | 211.22–211.34 | Quality control unit, qualifications, training, responsibilities and consultants |
| C | Buildings and Facilities | 211.42–211.58 | Facility design, ventilation, sanitation and maintenance |
| D | Equipment | 211.63–211.72 | Equipment suitability, cleaning, maintenance and automated equipment |
| E | Control of Components and Drug Product Containers and Closures | 211.80–211.94 | Receipt, quarantine, sampling, testing, approval or rejection, and container and closure controls |
| F | Production and Process Controls | 211.100–211.115 | Written procedures, in-process controls, contamination prevention and reprocessing |
| G | Packaging and Labeling Control | 211.122–211.137 | Packaging and labeling controls, operations and expiration dating |
| H | Holding and Distribution | 211.142–211.150 | Warehousing and distribution procedures |
| I | Laboratory Controls | 211.160–211.176 | Specifications, testing, release, stability and reserve samples |
| J | Records and Reports | 211.180–211.198 | Records, batch review, discrepancy investigations and complaints |
| K | Returned and Salvaged Drug Products | 211.204–211.208 | Evaluation and disposition of returned and salvaged products |
Requirements to check in practice
The table locates a requirement. It does not capture each section's conditions or exceptions.
Quality authority and training
Section 211.22 requires a quality control unit with authority to approve or reject specified materials and drug products. That authority includes products manufactured or held under contract, as well as relevant procedures and specifications. The unit's responsibilities and procedures must be written.
Personnel need suitable education, training, experience or a combination under section 211.25. CGMP training must continue at sufficient frequency and be conducted by qualified individuals. The section does not prescribe a universal annual training interval.
Incoming components and production procedures
A supplier's report is not an unconditional substitute for incoming testing. Section 211.84 requires lot sampling, testing or examination, and quality-unit release before use. Each component requires at least one identity test. Reliance on supplier results for other attributes depends on manufacturer identity testing and validation of supplier results at appropriate intervals.
Production and process procedures must be approved and followed. Section 211.100 requires contemporaneous documentation of the work, plus recorded and justified deviations. For sterile products, section 211.113(b) requires contamination-prevention procedures that include validation of aseptic and sterilization processes.
Laboratory controls and batch release
Section 211.160 requires scientifically sound, appropriate specifications, sampling plans and test procedures. Section 211.165 calls for a laboratory determination that the batch meets final specifications, including identity and strength of each active ingredient, before release. The section has exceptions. Those exceptions are not a waiver of final specifications, or of finishing the pending tests.
Passing finished-product tests is only part of the release decision. Under section 211.192, the quality unit must review and approve production and control records before batch release or distribution.
Stability has its own requirements. Section 211.166 requires a written stability program supporting storage conditions and expiration dates. It calls for an adequate number of batches, rather than a universal three-batch rule. Read expiration-dating requirements with the qualifications and exceptions in section 211.137.
Records, investigations and complaints
Record retention cannot be reduced to "keep all GMP records for one year." Section 211.180(a) generally requires batch-associated records for at least one year after the batch's expiration date. Specified expiration-date-exempt OTC batches instead require three years after distribution. Other record categories have qualifications. Section 211.180(e) also requires evaluation of product quality standards at least annually, under written procedures that are followed. The review is there to decide whether specifications, or manufacturing or control procedures, need to change.
Section 211.192 requires thorough investigation of unexplained discrepancies and specification failures, whether or not the batch has been distributed. Investigations must extend to potentially associated batches and products.
Complaints require written procedures covering oral and written complaints, quality review and assessment of the need for investigation. Section 211.198 does not automatically require a full investigation of every complaint.
Where to read 21 CFR Parts 210 and 211
Use the live eCFR pages for Part 210 and Part 211. This guide uses official text displaying currency through 29 October 2026. A last-amended date shown for the whole of Title 21 is not the amendment date of either part.
RegAffairs AI has an answer about FDA manufacturing rules for finished medicines.
If you need a PDF, GovInfo provides Part 211 from the 2025 annual edition, revised 1 April 2025. It is a dated edition, not a continuously updated consolidation. Its revision date precedes the December 2025 medical-gas scope change. Check the live text before relying on it for current requirements.